RecruitingPhase 1NCT05152290
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for SCI
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Spinal Cord Injury
Sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Enrollment
20 participants
Start Date
Jul 6, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Spinal Cord Injury.
Eligibility
Inclusion Criteria2
- Diagnosis of Spinal Cord Injury
- Understanding and willingness to sign a written informed consent document
Exclusion Criteria11
- Active infection
- Active cancer
- Chronic multisystem organ failure
- Pregnancy
- Clinically significant Abnormalities on pre-treatment laboratory evaluation
- Medical condition that would (based on the opinion of the investigator) compromise patient's safety.
- Continued drug abuse
- Pre-menopausal women not using contraception
- Previous organ transplant
- Hypersensitivity to sulfur
- Anticoagulation medicine use
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALAlloRx
cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05152290
Related Trials
Deciphering Preserved Autonomic Function After Spinal Cord Injury
NCT044933721 location
Pain Phenotyping in Patients With Neuropathic Pain After Spinal Cord Injury
NCT064432811 location
ARC-IM System to Manage Symptomatic Blood Pressure Instability Secondary to Chronic Spinal Cord Injury
NCT0714729612 locations
Nomad P-KAFO Study
NCT056445221 location
Improving Adherence to Spinal Cord Injury Exercise Guidelines Using Smartphone Technology and E-coaching
NCT054241721 location